Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study-Reference-Cited by-同舟云学术

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Published:2019-09 Issue:9 Volume:6 Page:e480-e488
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Ravandi Farhad,Assi Rita,Daver Naval,Benton Christopher B,Kadia Tapan,Thompson Philip A,Borthakur Gautam,Alvarado Yesid,Jabbour Elias J,Konopleva Marina,Takahashi Koichi,Kornblau Steven,DiNardo Courtney D,Estrov Zeev,Flores Wilmer,Basu Sreyashi,Allison James,Sharma Padmanee,Pierce Sherry,Pike Allison,Cortes Jorge E,Garcia-Manero Guillermo,Kantarjian Hagop M

Funder

MD Anderson Cancer Center

BMS

MD Anderson Cancer Center Leukaemia SPORE

Publisher

Elsevier BV

Subject

Hematology

Reference31 articles.

1. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia;Yates;Cancer Chemother Rep,1973

2. Emerging therapeutic drugs for AML;Stein;Blood,2016

3. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center;Walter;Leukemia,2015